Price movement over the last 24 hours
ADMA Biologics Inc vs Constellation Energy Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Constellation Energy Corporation trades at $241.86 (market cap $85.60B). The key difference: Constellation Energy Corporation is far larger — about 40.2× ADMA Biologics Inc's market cap, and Constellation Energy Corporation pays a 0.71% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CEG | |
|---|---|---|
Market Cap | $2.13B | $85.60B |
Sector | Health | Energy |
52-Week High | $20.38 | $403.95 |
52-Week Low | $7.60 | $236.50 |
Enterprise Value | $2.20B | $107.27B |
Dividend Yield | — | 0.71% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CEG trades at $245.87, up 2.77% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in two of the last three quarters. The company benefits from rising AI-driven electricity demand and long-term nuclear power purchase agreements with major clients like Walmart and Meta. Cash flow from operations remains robust at $4.24 billion for 2025, supporting dividend payments and growth investments.
The stock presents a compelling opportunity with a consensus price target of $343.50, implying significant upside. However, risks include high capital expenditures in 2026 leading to negative net cash flow and competitive pressures in the utilities sector. Analyst sentiment is strongly bullish with 70% buy ratings, but technical indicators suggest near-term caution.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →